Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cantor Fitzgerald analyst Josh Schimmer reiterates Insmed (NASDAQ:INSM) with a Overweight.
HC Wainwright & Co. analyst Andrew Fein reiterates Insmed (NASDAQ:INSM) with a Buy and maintains $90 price target.
Truist Securities analyst Nicole Germino maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $88 to $85.
HC Wainwright & Co. analyst Andrew Fein reiterates Insmed (NASDAQ:INSM) with a Buy and maintains $90 price target.
TD Cowen analyst Ritu Baral maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $75 to $98.
UBS analyst Trung Huynh maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $78 to $84.
